EP1067920A4 - Verfahren und zusammensetzungen zur hemmung von uv-induzierten kollagensynthesishemmung in menschlichen haut - Google Patents

Verfahren und zusammensetzungen zur hemmung von uv-induzierten kollagensynthesishemmung in menschlichen haut

Info

Publication number
EP1067920A4
EP1067920A4 EP99918456A EP99918456A EP1067920A4 EP 1067920 A4 EP1067920 A4 EP 1067920A4 EP 99918456 A EP99918456 A EP 99918456A EP 99918456 A EP99918456 A EP 99918456A EP 1067920 A4 EP1067920 A4 EP 1067920A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
radiation
compositions
reducing
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99918456A
Other languages
English (en)
French (fr)
Other versions
EP1067920A1 (de
Inventor
Gary J Fisher
John J Voorhees
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Publication of EP1067920A1 publication Critical patent/EP1067920A1/de
Publication of EP1067920A4 publication Critical patent/EP1067920A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35Ketones, e.g. benzophenone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/671Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52Stabilizers
    • A61K2800/522Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99918456A 1998-04-02 1999-04-02 Verfahren und zusammensetzungen zur hemmung von uv-induzierten kollagensynthesishemmung in menschlichen haut Withdrawn EP1067920A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8043798P 1998-04-02 1998-04-02
PCT/US1999/007267 WO1999051220A1 (en) 1998-04-02 1999-04-02 Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin
US80437P 2008-07-14

Publications (2)

Publication Number Publication Date
EP1067920A1 EP1067920A1 (de) 2001-01-17
EP1067920A4 true EP1067920A4 (de) 2003-01-02

Family

ID=22157383

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99918456A Withdrawn EP1067920A4 (de) 1998-04-02 1999-04-02 Verfahren und zusammensetzungen zur hemmung von uv-induzierten kollagensynthesishemmung in menschlichen haut

Country Status (11)

Country Link
EP (1) EP1067920A4 (de)
JP (1) JP2002510621A (de)
KR (1) KR20010042422A (de)
CN (1) CN1303282A (de)
AR (1) AR018826A1 (de)
AU (1) AU740569B2 (de)
BR (1) BR9909899A (de)
CA (1) CA2326507A1 (de)
HK (1) HK1038514A1 (de)
TW (1) TWI234455B (de)
WO (1) WO1999051220A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100377397B1 (ko) * 1999-12-23 2003-03-26 주식회사 대웅 레티놀 및 표피성장인자를 함유하는 피부보호 화장료 조성물
MXPA03000089A (es) * 2000-06-26 2004-09-13 Univ Michigan Uso de inhibidores de cinasa de tirosina de proteina de egf-r para prevenir el fotoenvejecimiento de la piel humana.
JP4612180B2 (ja) * 2000-12-19 2011-01-12 株式会社ヤクルト本社 皮膚外用剤
GB0319497D0 (en) * 2003-08-19 2003-09-17 Novartis Ag Organic compounds
KR100879558B1 (ko) * 2007-07-31 2009-01-22 라이브켐 주식회사 디벤조­파라­디옥신 유도체를 유효성분으로 함유한 피부보호 및 개선제
WO2009122540A1 (ja) * 2008-03-31 2009-10-08 株式会社資生堂 しわを防止または改善するための経口、注射、皮膚外用剤および美容方法
KR20160003188A (ko) * 2008-03-31 2016-01-08 가부시키가이샤 시세이도 주름을 방지 또는 개선하기 위한 경구, 주사, 피부 외용제 및 미용 방법
EP2153814A1 (de) 2008-08-05 2010-02-17 Isdin S.A. Verwendung von harnstoffhaltigen Zusammensetzungen
EP2153815A1 (de) 2008-08-05 2010-02-17 Isdin S.A. Verwendung von harnstoffhaltigen Zusammensetzungen

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid
JPS6061513A (ja) * 1983-09-14 1985-04-09 Sansho Seiyaku Kk 化粧料
EP0358528A2 (de) * 1988-09-09 1990-03-14 Unilever Plc Kosmetisches Präparat
JPH02142713A (ja) * 1988-11-25 1990-05-31 Shiseido Co Ltd 皮膚外用剤
JPH08245362A (ja) * 1995-03-08 1996-09-24 Seikagaku Kogyo Co Ltd 紫外線損傷防御用外用剤
EP0781551A1 (de) * 1995-12-29 1997-07-02 Advanced Polymer Systems, Inc. Retinoid-Formulierungen in porösen Mikrokugeln für verringerte Irritation und verbesserte Stabilität
WO1997046208A2 (en) * 1996-06-07 1997-12-11 Mt. Sinai School Of Medicine Of The City Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
WO1998030215A1 (en) * 1997-01-13 1998-07-16 Cilag Ag Liposome-based topical tretinoin formulation
WO1999036050A1 (en) * 1997-12-24 1999-07-22 Novogen Research Pty. Ltd. Compositions and method for protecting skin from uv induced immunosuppression and skin damage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810489A (en) * 1986-12-04 1989-03-07 Bristol-Myers Company High oil phase pharmaceutical vehicles and sunscreen compositions having waterproof sun protection factors
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids
US5690947A (en) * 1996-08-30 1997-11-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4108880A (en) * 1975-11-03 1978-08-22 Johnson & Johnson Esters of retinoic acid
JPS6061513A (ja) * 1983-09-14 1985-04-09 Sansho Seiyaku Kk 化粧料
EP0358528A2 (de) * 1988-09-09 1990-03-14 Unilever Plc Kosmetisches Präparat
JPH02142713A (ja) * 1988-11-25 1990-05-31 Shiseido Co Ltd 皮膚外用剤
JPH08245362A (ja) * 1995-03-08 1996-09-24 Seikagaku Kogyo Co Ltd 紫外線損傷防御用外用剤
EP0781551A1 (de) * 1995-12-29 1997-07-02 Advanced Polymer Systems, Inc. Retinoid-Formulierungen in porösen Mikrokugeln für verringerte Irritation und verbesserte Stabilität
WO1997046208A2 (en) * 1996-06-07 1997-12-11 Mt. Sinai School Of Medicine Of The City Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
WO1998030215A1 (en) * 1997-01-13 1998-07-16 Cilag Ag Liposome-based topical tretinoin formulation
WO1999036050A1 (en) * 1997-12-24 1999-07-22 Novogen Research Pty. Ltd. Compositions and method for protecting skin from uv induced immunosuppression and skin damage

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
CARCINOGENESIS. ENGLAND JAN 1996, vol. 17, no. 1, January 1996 (1996-01-01), pages 73 - 77, ISSN: 0143-3334 *
DATABASE MEDLINE [online] January 1996 (1996-01-01), WEI H ET AL: "Inhibition of UV light- and Fenton reaction-induced oxidative DNA damage by the soybean isoflavone genistein.", XP002218353, Database accession no. NLM8565140 *
DATABASE WPI Section Ch Week 198520, Derwent World Patents Index; Class D21, AN 1985-120196, XP002218354 *
DATABASE WPI Section Ch Week 199648, Derwent World Patents Index; Class B05, AN 1996-482093, XP002202753 *
FISHER G J ET AL: "RETINOIC ACID INHIBITS INDUCTION OF C-JUN PROTEIN BY ULTRAVIOLET RADIATION THAT OCCURS SUBSEQUENT TO ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE PATHWAYS IN HUMAN SKIN IN VIVO", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 6, no. 101, 15 March 1998 (1998-03-15), pages 1432 - 1440, XP001074731, ISSN: 0021-9738 *
GRIFFITHS CHRISTOPHER E M ET AL: "Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid).", NEW ENGLAND JOURNAL OF MEDICINE, vol. 329, no. 8, 1993, pages 530 - 535, XP000889997, ISSN: 0028-4793 *
KANG S ET AL: "PHOTOAGING AND TOPICAL TRETINOIN THERAPY, PATHOGENESIS, AND PREVENTION", ARCHIVES OF DERMATOLOGY, XX, XX, vol. 10, no. 133, October 1997 (1997-10-01), pages 1280 - 1284, XP008003909, ISSN: 0003-987X *
KLIGMAN L H ET AL: "TOPICAL RETINOIC ACID ENHANCES THE REPAIR OF ULTRAVIOLET DAMAGED DERMAL CONNECTIVE TISSUE", CONNECTIVE TISSUE RESEARCH, GORDON AND BREACH SCIENCE PUBLISHERS, US, vol. 12, 1984, pages 139 - 150, XP000576293, ISSN: 0300-8207 *
KLIGMAN L H: "PHOTOAGING MANIFESTATIONS, PREVENTION, AND TREATMENT", DERMATOLOGIC CLINICS, W.B. SAUNDERS CO., LONDON, GB, vol. 3, no. 4, July 1986 (1986-07-01), pages 517 - 528, XP008003894, ISSN: 0733-8635 *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 386 (C - 0750) 21 August 1990 (1990-08-21) *
SCHWARTZ E ET AL: "TOPICAL ALL-TRANS RETINOIC ACID STIMULATES COLLAGEN SYNTHESIS IN-VIVO", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 96, no. 6, 1991, pages 975 - 978, XP008003907, ISSN: 0022-202X *
See also references of WO9951220A1 *
WANG Y ET AL: "Inhibition of ultraviolet B-induced c-fos and c-jun expression in vivo by soybean isoflavone genistein.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 37, 1996, 87th Annual Meeting of the American Association for Cancer Research;Washington, D.C., USA; April 20-24, 1996, 1996, pages 270, XP008009935, ISSN: 0197-016X *
WEI HUACHEN ET AL: "Protection of ultraviolet B radiation-induced photodamage in hairless mouse and human skin by isoflavone genistein.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 108, no. 4, 1997, Annual Meeting of the Society for Investigative Dermatology;Washington, D.C., USA; April 23-27, 1997, pages 666, XP008009949, ISSN: 0022-202X *
WEISS J S ET AL: "TOPICAL TRETINOIN IMPROVES PHOTOAGED SKIN A DOUBLE-BLIND VEHICLE-CONTROLLED STUDY", JAMA THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, CHICAGO,IL, US, vol. 259, no. 4, 22 January 1988 (1988-01-22), pages 527 - 532, XP000576282, ISSN: 0098-7484 *

Also Published As

Publication number Publication date
AU3637499A (en) 1999-10-25
WO1999051220A1 (en) 1999-10-14
TWI234455B (en) 2005-06-21
BR9909899A (pt) 2000-12-26
CA2326507A1 (en) 1999-10-14
EP1067920A1 (de) 2001-01-17
JP2002510621A (ja) 2002-04-09
KR20010042422A (ko) 2001-05-25
HK1038514A1 (zh) 2002-03-22
WO1999051220A9 (en) 2000-04-27
CN1303282A (zh) 2001-07-11
AU740569B2 (en) 2001-11-08
AR018826A1 (es) 2001-12-12

Similar Documents

Publication Publication Date Title
EP0906077A4 (de) Hautpflegemittel
GB2308811B (en) Use of vitamin C or derivatives or analogues thereof for promoting skin elastin synthesis
IL141429A0 (en) Compositions and methods for treatment of mitochondrial diseases
FR2751874B1 (fr) Nouvelles compositions cosmetiques pour embellir et eclaircir la peau
MA22240A1 (fr) Compositions de soin de la peau
DE60043692D1 (de) Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
EP0884996A4 (de) Hautpflegemittel
PT914118E (pt) 3,5-difenil-1,2,4-triazoles substituidos e sua utilizacao como quelantes farmaceuticos de metais
BR9607726A (pt) Dispositivo e método para retração de tecido gengival
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
FR2688136B1 (fr) Composition cosmetique contenant des pigments melaniques en association avec certains tocopherols, et procede de protection de la peau, des cheveux, des muqueuses et des compositions cosmetiques.
ITMI991794A0 (it) Metodo ed apparecchiatura per l'esposizione dinamica ai raggi ultravio letti
DE69611444D1 (de) Amid-derivate und zusammensetzungen zur äusserlichen haut- und haarpflege
FR2687572B1 (fr) Utilisation de certains flavonouides dans des compositions cosmetiques, et procede de protection de la peau, ses phaneres et des compositions cosmetiques.
FR2757370B1 (fr) Plaque perfectionnee d'osteosynthese femorale
EP1067920A4 (de) Verfahren und zusammensetzungen zur hemmung von uv-induzierten kollagensynthesishemmung in menschlichen haut
ITRM940570A0 (it) "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee"
ZA969471B (en) Synthesis of quaternary melanin compounds and their use as hair dyes or for skin treatment
PL337064A1 (en) Method of and compositions for orally administering taxanes to human beings
FR2795639B1 (fr) Compositions pour la coloration artificielle de la peau et utilisations
FR2757635B1 (fr) Procede d'evaluation des dommages induits dans la peau par les uv-a
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
EP1214040A4 (de) Orangenschalenextrakte zur prevention und behandlung von krebs
FR2723316B1 (fr) Compositions et preparations depigmentantes de la peau, a usages pharmaceutiques ou cosmetiques
DK0700897T3 (da) L-carnitinsalt og kosmetiske og farmaceutiske præparater indeholdende samme til behandling af hudsygdomme

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001030

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/20 A, 7A 61K 31/12 B, 7A 61K 31/235 B, 7A 61K 31/35 B, 7A 61K 31/17 B, 7A 61K 31/07 B, 7A 61K 31/52 B, 7A 61K 31/165 B

A4 Supplementary search report drawn up and despatched

Effective date: 20021113

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040315

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060215